Viatris Stock Price and Value Analysis

Viatris (NASDAQ:VTRS) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold Viatris to reach your target.

Target type

VTRS Free Cash Flow Trend

Free Cash Flow trendline for VTRS
Free Cash Flow trendline for Viatris
CSV

Based on historical returns, we believe that Viatris can grow its free cash at a rate of about 3%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is making money at a modest rate.
  • This company is less known than others.
  • This stock looks fairly priced.

Inside the VTRS Numbers

VTRS Price
(Viatris stock price per share)
$19.63
[?] VTRS Fair Price
(based on intrinsic value)
$20.02
[?] VTRS Safety Price (based on a variable margin of safety) $12.01
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 26% lower than other Healthcare stocks
[?] PE Ratio versus Industry 0% lower than other Drug Manufacturers - General stocks
[?] Free Cash Flow Jitter 26%
[?] Dividend Yield 2.41% (tax impact)
Shares Shorted 35,240,834

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

Recent Insider Activity

Open-market buys and sells reported by Viatris's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2024-11-11 Campbell Paul (See Remarks) Sell 26,925 $12.88
2024-09-12 Malik Rajiv Sell 139,681 $11.66
2024-09-12 Malik Rajiv Sell 60,319 $11.71
2024-08-30 Malik Rajiv Sell 50,000 $12.00
2024-08-28 Malik Rajiv Sell 50,000 $11.90
2024-08-23 Malik Rajiv Sell 100,000 $11.75
2024-08-22 Malik Rajiv Sell 100,000 $11.73
2024-08-21 Malik Rajiv Sell 100,000 $11.75
2024-06-14 Malik Rajiv Sell 264,300 $10.18
2024-06-13 Malik Rajiv Sell 85,660 $10.52

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 35,240,834 shares shorted. With 1,139,461,355 shares available for purchase and an average trading volume over the past 10 trading days of 11,660,120, it would take at least 3.0 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2018 1792044 2,090
2019 1792044 1,571
2020 1792044 996
2021 1792044 2,726
2022 1792044 2,685
2023 1792044 2,561
2024 1792044 1,941
2025 1792044 1,927

Download the yearly data as CSV.

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 4 fiscal years from 2018 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $8,518 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

Trendshare has no dividend payment facts for these years, so the table shows no dividends. That is a gap in the data, not a finding about the company.

In 4 of the 4 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $1,433 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, cash spent repurchasing shares was $501 million, 26.0% of estimated free cash flow of $1,927 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2018 2,090 n/a 432 432 20.7%
2023 2,561 n/a 250 250 9.8%
2024 1,941 n/a 250 250 12.9%
2025 1,927 n/a 501 501 26.0%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $11,434 million in 2018 and $14,300 million in 2025, a compound annual growth rate of 3.2% over 7 years.

Revenue fell 3.0% from 2024 to 2025.

Our estimated free cash flow was $1,927 million in 2025, 13.5% of revenue. In 2018 the estimated margin was 18.3%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2018 11,434 2,090 18.3%
2019 11,501 1,571 13.7%
2020 11,946 996 8.3%
2021 17,886 2,726 15.2%
2022 16,263 2,685 16.5%
2023 15,427 2,561 16.6%
2024 14,739 1,941 13.2%
2025 14,300 1,927 13.5%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $1,322 million against total liabilities of $22,482 million, or 5.9% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 60.4% of total assets in 2025, compared with 62.0% in 2019, a decrease of 1.5 percentage points.

Stockholders equity was $14,711 million in 2025, compared with $11,884 million in 2019, a rise of 23.8%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 6.7% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2019 31,256 476 19,372 11,884
2020 61,553 844 38,599 22,954
2021 54,843 701 34,350 20,493
2022 50,022 1,260 28,950 21,072
2023 47,686 992 27,218 20,467
2024 41,501 735 22,865 18,636
2025 37,193 1,322 22,482 14,711

Price Versus Our Estimated Value

Free cash flow was positive in all 8 fiscal years we have for Viatris under its current SEC filer.

The latest three years average $2,143 million in free cash flow against $1,552 million for the earliest three, which is a sharp rise.

Free cash flow is uneven from year to year, with a variability measure of 26%.

The price of $19.63 falls between the safe value ($12.01) and fair value ($20.02) for Viatris.

Viatris pays a dividend yield of 2.41%.

Our value investing guide explains how to test these numbers against the filings themselves.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 26% below the average for stocks in the Healthcare sector.

Its trailing P/E ratio is in line with the average for stocks in the Drug Manufacturers - General industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Viatris, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
Viatris (VTRS) 22,505 - 2.4% - 2% below
United Therapeutics Corporation (UTHR) 23,625 20.9 - 1.5% 30% above
Jazz Pharmaceuticals plc (JAZZ) 14,780 68.1 - 3.4% 53% below
Zoetis (ZTS) 32,144 13.5 2.6% - 865% above
Elanco Animal Health Incorporated (ELAN) 12,866 - - - 96% above
Alkermes plc (ALKS) 7,552 - - 1.5% 315% above
Corcept Therapeutics Incorporated (CORT) 7,112 48.9 - 0.0% 858% above

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 1792044.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: VTRS annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in VTRS

Does Viatris have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: VTRS

This example shows how we apply the Trendshare checklist to VTRS: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 19.63
    • Market cap: $23B
    • EPS: -0.53
  2. Step 2 — Valuation checks

    • P/E: —
    • FCF yield: —
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.